Maria Araceli obtained her Biochemistry Degree from the Faculty of Chemical and Pharmaceutical Sciences of the University of Chile, after completing her undergraduate thesis at the Gene Therapy Laboratory of said University.
Driven by the interest in knowing in depth about the health technologies of the new millennium, Maria Araceli did her doctorate at the same Faculty of Chemical and Pharmaceutical Sciences of the University of Chile. This time, she focused her doctoral thesis in the field of Cellular Therapy. Subsequently, to incorporate the necessary tools to put these new concepts of "pharmacology" into clinical practice, she completed a certification in Clinical Studies and Clinical Monitoring at the University of Chile. For several years she served as a Pharmacology professor at various universities, participating in the training of doctors, nurses and dentists.
In the effort to contribute to the dissemination of science, pharmacology and the ethical use of medicines from the private sphere, Maria Araceli joined the pharmaceutical industry in 2012. During this time, she has had the opportunity to work closely with opinion leaders in the areas of expertise of Oncology, Hematology, Cardiology, Pain, Diabetes, Obesity and Vascular Neurology.
Maria Araceli's mission is to spread the science behind the efficient and safe management of stroke, working hand in hand with the main opinion leaders. In addition, among her objectives are to encourage research in the field of stroke, thereby generating new local evidence that supports decision-making at the public policy level. It promotes the articulation between the different medical specialties, the various societies, patient associations, universities, clinics, hospitals, government entities and pharmaceutical companies for joint work in favor of improving the prevention and timely treatment of stroke patients.